• Crohn's disease clinical trial

    Restoring normal immune function to treat Crohn’s disease

    LEARN MORE
  • Qu Biologics has begun a clinical trial in recurrent lung cancer

    LEARN MORE
  • Meet our team

    “You can teach skills, but you can’t teach character. We hire character.” Dr. Hal Gunn, CEO.

    LEARN MORE

"The future of medicine lies in treatments that restore our body's innate capacity to heal."

~ Dr. Hal Gunn, CEO of Qu Biologics

Qu Biologics is at the forefront of a paradigm shift in the way we treat cancer and other immune-related disease. Rather than blocking or stimulating a single receptor or pathway, the company’s Site Specific Immunomodulators (SSIs) aim to restore the body’s normal immune response.

About Qu Biologics

Qu Biologics has discovered how our body’s immune response to acute infection helps our body clear cancer and other chronic inflammatory diseases. To learn more, read How SSIs Work. SSIs, which are derived from components of inactivated bacteria, are designed to activate the body’s innate immune response and restore normal immune function in the targeted organ or tissue, to reverse the chronic inflammation underlying many chronic diseases, including cancer, inflammatory bowel disease and other immune-related conditions. By restoring and empowering your own immune system, SSIs are designed to treat disease differently.

We bring excitement and passion to our work every day with the goal of creating treatments that will positively impact the lives of people living with chronic disease. Qu Biologics’ founder and CEO, Dr. Hal Gunn, is a clinician who for 20 years has worked to understand the link between our immune system and chronic disease, including cancer. Qu Biologics’ Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, leads Qu’s growing clinical trial program. Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology at the Geisel School of Medicine at Dartmouth College and recognized expert in immune cell trafficking to tumours, leads a growing team of Qu scientists investigating new promising applications of SSIs.

Currently, we are recruiting participants for a Health Canada-approved randomized clinical trial to assess the safety and efficacy of SSI therapy for the treatment of Crohn’s disease. More information about this Crohn’s disease research trial and participation can be found at www.qucrohnstrial.com.

We also have begun a Health Canada-approved clinical trial to research SSI treatment in recurrent lung cancer. To learn more about this clinical trial, read Clinical Trials Lung Cancer or call the BC Cancer Agency Research Centre’s Lung Health Study line at 604-675-8088.

A Phase 2a trial in ulcerative colitis is planned to begin enrolment in Q2 2015. To learn more about this trial, read Clinical Trials Ulcerative Colitis.

Upcoming Events

  1. Bloom Burton Healthcare Investor Conference

    May 4 - May 5
  2. BIO International Convention

    June 15 - June 18
  3. BIO Investor Forum

    October 20 - October 21

Twitter Widget Plus

About SSIs Discovery

Our History

Qu Biologics was launched in 2007 by Dr. Hal Gunn and Rob Freeman.

LEARN MORE >

Careers

Join a team of innovators who share a passion to make a difference.

LEARN MORE >

How SSI Work

SSIs are designed to restore your normal immune response.

LEARN MORE >

Efficacy and Safety Studies

More than 270 patients have been treated with SSI therapy in a compassionate use program.

LEARN MORE >